Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Certified Advisory Corp

Certified Advisory Corp cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,477 shares of the biopharmaceutical company’s stock after selling 222 shares during the period. Certified Advisory Corp’s holdings in Gilead Sciences were worth $878,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in GILD. Avior Wealth Management LLC grew its stake in shares of Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock worth $782,000 after purchasing an additional 108 shares in the last quarter. Concord Asset Management LLC VA grew its position in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 111 shares in the last quarter. TFB Advisors LLC increased its stake in Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after buying an additional 116 shares during the period. Sumitomo Life Insurance Co. raised its position in shares of Gilead Sciences by 0.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 117 shares in the last quarter. Finally, FDx Advisors Inc. raised its position in shares of Gilead Sciences by 2.2% during the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 117 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 0.5 %

Shares of Gilead Sciences stock opened at $90.19 on Friday. The company has a market cap of $112.40 billion, a price-to-earnings ratio of 1,002.11, a PEG ratio of 2.78 and a beta of 0.17. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company’s fifty day simple moving average is $87.43 and its 200-day simple moving average is $76.86. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the firm posted $2.29 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 4.38 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.42%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Analyst Ratings Changes

GILD has been the subject of a number of research reports. Wells Fargo & Company increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Piper Sandler upped their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. UBS Group raised their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, Truist Financial boosted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Twelve investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $95.41.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.